News

FDA Approves CSL's ANDEMBRY, First Factor XIIa-Targeting HAE Prophylactic For Patients 12+
CANBERA (dpa-AFX) - CSL (CSLLY, CSL.AX) announced that the U.S. Food and Drug Administration approved ANDEMBRY (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use ...